SGLT2抑制剂坎格列净的临床应用研究进展

Clinical research progress of SGLT2 inhibitor canagliflozin

坎格列净是一种钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,通过阻断肾脏对葡萄糖的重吸收及增加尿液中葡萄糖的排泄,降低血糖。多个临床研究证明其可以有效控制2型糖尿病患者的血糖,改善患者Hb A1c水平,同时可降低患者体质量及收缩压。坎格列净不良反应主要有尿路感染、生殖道霉菌感染等,单药使用较少出现低血糖反应,患者对其有较好的耐受性。本文对坎格列净治疗2型糖尿病的机制、药效学、药动学、有效性和安全性等方面的研究进展进行了综述。

Canagliflozin is an inhibitor of sodium-glucose co-transporter-2. It can reduce glucose reabsorption in proximal tubules and increase urinary glucose excretion,resulting in decreased plasma glucose. Canagliflozin is effective in reducing glucose levels in patients with type 2 diabetes. It also can reduce body weight and systolic blood pressure. Main adverse effects of canagliflozin include urinary tract infections and genital mycotic infections. Risk of hypoglycemia is low during canagliflozin monotherapy. This paper summarizes mechanism,pharmacodynamics,pharmacokinetics,efficacy and safety of canagliflozin in treatment of type 2 diabetes.